1. Introduction {#s0005}
===============

The human *APOE* gene has three alleles: ε2, ε3 and ε4. Possession of an ε4 allele (compared to ε3) has been linked to a higher risk of developing and earlier age at onset of late onset Alzheimer's disease (AD) ([@b0120]) with evidence of an allele dose effect ([@b0050]). One ε4 allele confers a threefold increase in risk and possession of two ε4 alleles confers an over tenfold increase in risk ([@b0050]). Possession of an ε2 allele has been linked with a lower risk of AD and may also slow progression of vascular cognitive impairment ([@b0055], [@b0115], [@b0195], [@b0310]).

Possession of an ε4 allele is neither necessary nor sufficient for the development of AD and many ε4 allele carriers live to advanced ages with no evidence of dementia ([@b0085]). It has been suggested that ε4 reduces the age at onset of AD but does not influence whether someone develops it ([@b0235]). Studies over several decades have reported that ε4 allele possession may have more of a deleterious effect in women (reviewed in ([@b0325])).

It has been shown in post-mortem brain studies and in PET studies of older adults that ε4 allele possession is associated with higher levels of amyloid plaques ([@b0100], [@b0355]). In one study this effect was seen even in middle-aged individuals ([@b0170]). ε4 effects on neurofibrillary tangles are much less consistent ([@b0260]). In contrast individuals with the ε2 variant have less AD neuropathology before extreme old age ([@b0045], [@b0255]).

Most previous studies of the effect of ε4 on cognition in non-demented adults have included older participants. Relatively few have studied younger people (only 8 studies with a mean age of under 50 y in a 2017 meta-analysis) or reported the presence of the ε2 allele ([@b0205]). Indeed in one study possession of ε2 was an exclusion criterion ([@b0150]). A meta-analysis in 2011 found evidence of improved episodic memory in ε2 carriers from 6 studies (mean effect size 0.09, 95% CI −0.05 to 0.22) ([@b0360]). The same meta-analysis reported that the adverse effects of ε4 on cognition (in the absence of dementia) increases with age, yet many previous studies have not adequately screened for dementia ([@b0360]). In particular many studies have used the mini mental state examination (MMSE) which is much less sensitive to the presence of early dementia (or mild cognitive impairment) than other tests such as the Addenbrooke's cognitive examination revised (ACE-R) ([@b0245]).

Although compromised by lack of phenotypic precision, a GWAS meta-analysis which analysed a general cognitive ability score from heterogeneous individual studies found that the effect of ε4 was minimal in middle age and increased with age ([@b0140]). Other studies have reported that the separation between ɛ4 carriers and non-ɛ4 carriers on cognitive tests starts in the mid 50 s ([@b0090]) and as early as 35 years old ([@b0080]). The largest recent study of middle aged adults, which used data from the Generation Scotland study, showed detrimental effects of ε4 on logical memory and processing speed. These effects appeared to be larger in those aged \>60 y in a sensitivity analysis ([@b0225]).

There remains considerable debate as to whether the changes seen in some previous studies reflect genuine ε4 effects in the absence of dementia, or merely the early stages of a dementing process. The latter is entirely possible as amyloid can be found in the brain at least 10 years before the diagnosis of a dementia ([@b0155], [@b0250]). Evidence of cognitive decline has been shown 10 and 12 years before the onset of AD ([@b0025], [@b0320]).

Perhaps unsurprisingly, given the known relationship of ε4 to AD risk, most previous studies have included a measure of episodic memory. The cognitive domains of attention, executive function and visuospatial function have been much less well studied ([@b0360]). In the 2011 meta-analysis by Wisdom et al. the mean effect size for ε44 homozygotes on episodic memory was −0.18 (95% CI −0.34 to −0.02) and for ε34 participants it was −0.04 (95%CI −0.09 to 0.01). There was also evidence of small ε4 effects on executive functioning (effect size −0.06, 95% CI −0.12 to −0.04) and perceptual speed (effect size −0.07, 95% CI −0.13 to −0.01) ([@b0360]). Although episodic memory is the major cognitive process affected early in LOAD, it is not the only process affected early in the disease process ([@b0040]). Poor working memory performance has been reported as one of the earliest deficits seen in Alzheimer\'s disease ([@b0230]). The current study builds on previous work by including younger participants, including a relatively large number of ε2+ participants, rigorously screening for dementia (to exclude this as a cause of any differences observed) and by testing multiple domains of cognition.

Whilst some individual studies have suggested that there is a positive pleiotropic effect of ε4 in younger adults (e.g. [@b0180]) a meta-analysis found no evidence of such an effect ([@b0185]). The authors suggested that this may have been because several of the studies used less difficult tasks that may have failed to pick up subtle effects.

We wished to study the effects of *APOE* genotype on cognition independent of dementia. We hypothesised that cognitive function is reduced in young to middle aged adults without dementia from the ALSPAC study with an ε4 allele compared to those without.

Recall by genotype is an efficient study design which allows causal inference, precision phenotyping and maximises statistical power ([@b0335]). It involves selecting a defined number of participants with each genotype at random from an existing study with genetic data. These participants are then invited to take part in the recall study. Dense phenotyping can be performed in the recall study which would be impracticable to perform on the whole study cohort.

2. Methods and materials {#s0010}
========================

2.1. Ethics {#s0015}
-----------

Ethical approval for this study and approval for substantial amendments was provided by the ALSPAC ethics and law committee (study ref E201109). Both researchers and participants were blind to *APOE* genotype status. All participants gave written informed consent to take part in this study following assessment of their capacity to do so by a Psychiatrist (LIS).

2.2. The Avon longitudinal study of parents and children {#s0020}
--------------------------------------------------------

The Avon Longitudinal Study of Parents and Children (ALSPAC) as described previously in detail is a prospective study which was established in 1991 ([@b0070], [@b0160]). Initially 14,541 women were enrolled, resulting in 14,062 live births and 13,988 children alive at one year. At age 7/8 further eligible children were added to the sample, giving a total sample size of 15,247 eligible pregnancies and 14,775 live births. Data were collected from self-report questionnaires, teacher report questionnaires, medical, educational and other records, birth registries, and hands on assessment. Detailed information has been collected since birth via questionnaires and at regular clinics. The study website contains details of all the available data through a fully searchable data dictionary (<http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/>).

2.3. APOE genotyping {#s0025}
--------------------

Genotyping of all study participants for *APOE* was undertaken by integrated single label liquid phase assay as previously described ([@b0005]). DNA samples were available in 2009 for 7091 children, 63% of the 11343 ALSPAC children with potential DNA samples available. In total 95% of these samples were genotyped ([@b0315]). After siblings and children of known non-white ethnicity were excluded there was genotype data for 5995 children. DNA samples were available in 2010 for 9763 mothers: 83.6% of the 11,679 mothers with potential DNA samples available. In total 87.9% of these samples were able to be genotyped. There was no strong evidence of a sex difference in genotype distribution or of a deviation from Hardy Weinberg Equilibrium for either the mothers or young people (p \> 0.05).

2.4. Recall by genotype {#s0030}
-----------------------

Inclusion criteria for this study were that participants had previously taken part in the ALSPAC study and that they had a known *APOE* genotype. Exclusion criteria were; drop out from ALSPAC; living \>50 miles away; already taking part in an ALSPAC sub-study; very poor command of English; lack of capacity to consent; and dementia.

Recruitment to the study is summarised in [Fig. 1](#f0005){ref-type="fig"}. The planned strategy was to identify whether a per-genotype difference existed between the homozygotes and then to ascertain whether there was an allele dose effect by inviting heterozygotes in a second wave. Due to a very poor response rate to the first wave the invitations to the second case selection were sent earlier than planned.Fig. 1The flow of potential participants through the study.

Participants in each batch of invitations were chosen at random from the case selection. They were sent an initial invitation, a reminder postcard after 3 weeks (if they had not replied) and if they had still not replied were contacted by telephone. All participants were reminded the day prior to their appointment. In order to maintain double blinding as to participant genotype, all invitation letters, case selections, telephone calls and participant contact other than the study visit were carried out by ALSPAC staff and not by the researchers.

Despite all of these measures the final response rate (either positive or negative) was only 16%. Participants and the rest of the ALSPAC study population were compared (see [Supplementary Table 1](#s0110){ref-type="sec"}).

2.5. Co-variates {#s0035}
----------------

Information was available on a range of possible confounders including IQ, blood pressure, serum cholesterol, past medical history, mood rating scales and demographic variables.

2.6. The study visit {#s0040}
--------------------

The study visit lasted for up to 3 h. Participants were screened for dementia using the ACE-R, which incorporates the MMSE ([@b0245]). Information was gathered on head injuries, history of mental illness, current medication, caffeine consumption, alcohol intake, illicit drug use and family history of dementia. All young people completed the moods and feelings questionnaire ([@b0035]). All mothers completed the Edinburgh Postnatal Depression Scale (EPDS) ([@b0125]) and the Crown-Crisp Inventory ([@b0130]). These questionnaires were chosen to allow comparison with data previously collected by ALSPAC. All participants completed the Depression, anxiety and stress scale (DASS) and the Cognitive Failures Questionnaire (CFQ) ([@b0075], [@b0215], [@b0220]). The DASS may be downloaded from [www.psy.unsw.edu.au/dass/](http://www.psy.unsw.edu.au/dass/){#ir010}. Full scale IQ was measured using the Wechsler abbreviated scale of intelligence (WASI) ([@b0345]).

The neuropsychological battery included the Rey Auditory Verbal Learning Test (RAVLT), bespoke episodic list learning and paired associative list learning tasks, a Stroop test, digit span, n-back, verbal fluency (FAS and animals), the Rey Osterrieth complex figure, trails A&B, simple & choice reaction time and a bespoke visual motion task ([@b0065], [@b0200], [@b0265], [@b0270], [@b0275], [@b0290], [@b0295], [@b0330], [@b0340]) Tests were carried out in a standard order and breaks were offered at two regular points. No feedback was offered to participants on how they had performed on the tests. The researcher was present during all tests. Participants were requested to refrain from smoking and to drink only one cup of their normal caffeinated beverage the morning of the study visit. This was to avoid the known effects of caffeine on performance in such tests ([@b0190]).

Participants were read standardised instructions for each task immediately before completing them. In the simple reaction time task participants were asked to press a response key as soon as they saw the stimulus. The interval between trials was a random value between 1000 ms and 1500 ms. In the choice reaction task participants were asked to press one key if the stimulus was red and a different key if it was green. The interval between trials was a random value between 1000 ms and 2000 ms.

In the Stroop task participants were requested to push one of three keys each time a stimulus was displayed, to indicate if the colour of the word was red, green or blue. Congruent, incongruent and neutral stimuli (XXX of the same length as the other words) were displayed until the participant responded. The interval between trials was a random value between 1000 ms and 1500 ms. There were up to 36 trials of each condition.

For the n-back task participants were asked to press the space bar if they recognised a letter as being the same as n letters back. The response key was the same in all conditions. Each letter was displayed for 2 s with a 1 s interval between letters.

During the visual motion task participants were asked to push; one key if the stimulus was going in the same direction as the other objects; and a different key if the stimulus was going in a different direction to the other objects. There were 3 different speeds that the stimulus moved at, with 30 trials at each speed. Each trial moved to the next when the participant pressed a key.

2.7. Statistical analysis {#s0045}
-------------------------

All analyses were carried out in STATA v13. There was no evidence to support an association of any demographic variables or potential confounders with *APOE* genotype ([Table 1](#t0005){ref-type="table"}). Given that participants with each genotype were selected at random and that genotypes are unlikely to be confounded in any case, it was decided not to include any co-variates in the analysis.Table 1Characteristics of the study population.Variableε2+ε33ε4+Statistical evidence (ANOVA or Mann Whitney)MeanSDMeanSDMeanSDWithin case selectionTook part in study333942$\text{p} \leqslant 0.0001$^\*^Did not take part in study721661788Mean age of mothers at visit (yrs)51.4244.86750.2823.99351.1434.459p = 0.513*Gender*Male201520Χ^2^ = 3.521Female132422p = 0.172Young Person (YP)222123Χ^2^ = 1.473Mother111819p = 0.479IQ114.3337.292112.92111.741113.48810.107Χ^2^ = 0.208p = 0.901Mini Mental State Examination (MMSE) score29.7880.41529.5530.8629.6670.612Χ^2^ = 0.732p = 0.693Addenbrooke's Cognitive Examination (ACE-R) score93.9093.07693.6764.13793.1673.963Χ^2^ = 0.460p = 0.795Positive family history of dementia (%)0.3940.2970.415Χ^2^ = 1.488p= 0.475History of a significant head injury (%)0.1520.2630.195Χ^2^ = 0.217p = 0.897No. of participants who use cannabis regularly3.5000.707000.7501.5N/ANo. of participants who use stimulants regularly0.5000.7070000N/ANo. of cups of caffeine containing drink usually consumes per day2.6042.043.4592.343.8393.144Χ^2^ = 3.034p= 0.219No. of cups of caffeine containing drink consumed that day0.6130.7150.730.8710.9021.934Χ^2^ = 0.046p= 0.977Units of alcohol per week10.34812.5199.45610.9977.4888.092Χ^2^ = 0.708p= 0.702Personal history of epilepsy0.0610.0260.024Χ^2^ = 0.895p = 0.639History of anxiety disorder0.1210.2370.190Χ^2^ = 1.445p = 0.486History of depression0.1210.1840.262Χ^2^ = 2.418p= 0.298History of psychotic disorder000N/ACrown-Crisp total score25.69736.98735.52638.232.66736.701Χ^2^ = 3.006p= 0.222Cognitive Failures Questionnaire Score30.12113.94432.26311.9538.92915.371Χ^2^ = 6.051p = 0.049^\*^Last available cholesterol (mothers) mmol/L4.8130.95.2020.9135.0490.536p \< 0.001^\*^Depression, Anxiety and Stress Scale (DASS) total score9.4249.5727.5536.76917.21416.389Χ^2^ = 7.487p = 0.024^\*^Edinburgh Postnatal Depression Scale (EPDS) total score4.2126.1435.7896.3385.696.426Χ^2^ = 1.022p = 0.600Moods & Feelings total score3.0612.852.4212.9373.5244.49Χ^2^ = 0.375p = 0.829

A power calculation estimated a total n of 350 i.e. 70 in each genotype group to ensure 80% power with an α of 0.05. It soon became apparent that this was not going to be possible so numbers were maximised wherever possible. To maximise study power an analysis strategy of combining ε32 and ε22 to form an ε2+ group and combining ε34 and ε44 to form an ε4+ group was used with ε33 as the reference group.

Transformation of variables was used where necessary to permit parametric testing. Where parametric testing was possible the data was initially analysed using ANOVA and subsequently by linear regression. Non-parametric testing was performed using the Kruskal-Wallis and Dunn's post hoc tests. Effect sizes were calculated, where possible, using the post hoc estate size command in Stata after ANOVAs.

For the N-back data multi-level regression was used, as described previously ([@b0285]). Unfortunately reaction times were not available for target/non-target so the reaction time data was only re-shaped according to the difficulty level. It was not possible to use multilevel regression for accuracy in the visual motion task as the data had a truncated normal distribution, but it was possible to use a repeated measures ANOVA.

For the simple reaction time all unfeasibly long (\>1000 ms) or short (\<120 ms) reaction times were excluded before calculation of mean and median reaction times. A further corrected (C-mean) mean reaction time was calculated by excluding all reaction times \>2SD away from the sub-mean. The C-mean was then used in analyses. For the choice reaction time task the same procedure was followed, except that the upper limit for excluding unfeasibly long reaction times was raised to 2000 ms. The difference between the choice C-mean and simple C-mean was calculated and used in the analysis as this is a purer measure of choice than the choice reaction time alone.

We made an a priori decision to exclude individuals with an ε42 genotype from analyses as this group mixes the high and lowest risk alleles. This is standard practice in *APOE* research (e.g. [@b0010]) We also made an a priori decision to exclude those who scored \<82 on the ACE-R as this has optimal sensitivity for dementia ([@b0245]).

3. Results {#s0050}
==========

3.1. Demographics {#s0055}
-----------------

The study population differed by *APOE* genotype from those in the case selection who did not take part (see [Table 1](#t0005){ref-type="table"}). In particular homozygotes for rare alleles were more likely to participate. The cause for this is unknown. Although homozygotes were invited first and then heterozygotes in the second wave of invitations the case selection was performed at random (other than for homozygotes for rare genotypes who were all invited to participate) and participants were then invited in a random order. There was no difference in the rate of family history of dementia between the groups. The expected effect of *APOE* genotype on serum LDL cholesterol was observed ([@b0365]). The age range of those who took part was 23--24 (young people) and 42--67 (mothers). There were 33 individuals with an ε2+ genotype with an age range of 23--24 (young people) and 43--67 (mothers). There were 39 individuals with an ε33 genotype whose ages ranged from 23 to 24 (young people) and 42 to 62 (mothers). Finally there were 42 individuals with an ε4+ genotype, with ages ranging from 23 to 24 (young people) and 42 to 62 (mothers).

3.2. Test battery results {#s0060}
-------------------------

There was little evidence of a per genotype difference in performance on the reaction time, digits forwards/backwards task, the Rey-Oesterrieth complex figure task or the Stroop test (see [Table 2](#t0010){ref-type="table"}). Although the initial ANOVA was suggestive of a per genotype difference in phonemic fluency (p = 0.047) no evidence of a difference was seen in a subsequent linear regression. There was no evidence of a per genotype difference in category fluency (p = 0.647).Table 2Results from the neuropsychological test battery. Χ^2^ refers to statistical evidence from the Kruskal Wallis test.Variableε2+ε33ε4+Statistical evidence (ANOVA or Kruskal Wallis)MeanSDMeanSDMeanSDDigits forwards6.0611.0295.9251.1855.9071.25p = 0.835Effect size = 0.003Digits backwards4.5761.4374.31.3814.1861.367p = 0.496Effect size = 0.013RAVLT trials I-V recall (errors)1.6362.1331.4252.0241.4191.918Χ^2^ = 1.205p = 0.547RAVLT trials I-V recall (repetitions)15.42412.2819.0510.58313.79115.239Χ^2^ = 4.650p = 0.098RAVLT trials I-V recall (total)57.8487.48452.710.11853.8847.582Χ^2^ = 6.663p = 0.036^\*^RAVLT trial VII delayed recall (errors)11.9692.90110.753.09511.2142.968Χ^2^ = 0.523p = 0.770RAVLT trial VII delayed recall (total)11.9692.90110.753.09511.2142.968Χ^2^ = 2.980p = 0.225Verbal fluency (FAS) total no. words43.6978.43241.2511.04741.18611.065p = 0.567Effect size = 0.010Category fluency (animals)23.6363.95921.855.32323.0934.83p = 0.355Effect size = 0.018Paired associative learning (errors)1.6671.9311.7251.9612.4652.693Χ^2^ = 2.907p = 0.234Paired associative learning (total)51.2427.0845.713.92146.6519.768Χ^2^ = 4.722p = 0.094Rey-Osterrieth figure delayed recall22.7884.69720.0757.60421.0936.045p = 0.317Effect size = 0.029Rey-Osterrieth figure immediate recall23.5615.27519.7388.25221.2446.073p = 0.104Effect size = 0.040Trails B -- Trails A (secs)20.5959.63636.74541.30133.83523.521Χ^2^ = 11.704p = 0.003^\*^Episodic list learning total recalled11.6972.68710.0753.214103.471Χ^2^ = 6.842p = 0.033^\*^Episodic list learning errors0.4240.7920.4750.8160.310.643Χ^2^ = 0.781p = 0.677C-mean simple reaction time (ms)292.04938.829284.92534.884289.37929.281Χ^2^ = 0.839p = 0.657C-mean choice reaction time (ms)438.10959.592440.35660.409446.22553.149p = 0.778Effect size = 0.004Choice RT error rate0.0360.0210.0410.0290.0470.042Χ^2^ = 1.990p = 0.370Stroop interference effect (ms)91.87895.07124.45494.421109.77584.805p = 0.324Effect size = 0.020

3.3. Episodic memory {#s0065}
--------------------

In the main analysis there was no evidence of a per genotype difference in performance at the long delay timepoint in the RAVLT (see [Fig. 2](#f0010){ref-type="fig"}B). As shown in [Fig. 2](#f0010){ref-type="fig"}A the ε2+ group remembered slightly more words in the first 5 trials of the RAVLT (5.1 more words, Χ^2^ = 6.663, p = 0.036) In addition there was evidence from both the Kruskal-Wallis and Dunn's tests that ε2 carriers performed better on the episodic list learning task (1.6 more words, Χ^2^ = 6.842, p = 0.016) (see [Fig. 3](#f0015){ref-type="fig"}). This was an immediate recall task. There was no evidence of a per-genotype difference in the paired associative learning task.Fig. 2Results from the RAVLT. There was evidence that the ε2+ group remembered more words in trials I-V (A) but no statistical evidence to support a between group difference at the long delay time point (B). The standard deviations for each group are shown in the error bars. A post hoc Dunn's test suggested that the ε2+ group remembered more words than either the ε33 group (p = 0.011) or the ε4+ group (p = 0.012). ^\*^ denotes p \< 0.05.Fig. 3Episodic list learning. The standard deviations for each group are shown in the error bars. There was evidence from a post-hoc Dunn's test that the ε2+ group performed better than the ε33 (p = 0.016) group and the e4+ group (p = 0.007). ^\*^ denotes p \< 0.05.

3.4. Executive functioning {#s0070}
--------------------------

There was reasonable strength evidence that those with an ε2 allele were faster (i.e. performed better) in the trails A&B test (Χ^2^ = 11.704, p = 0.003, see [Fig. 4](#f0020){ref-type="fig"}). The Kruskal-Wallis and Dunn's post hoc test suggested that there was a difference between the ε2+ group and the ε33 (p = 0.005) and the ε4+ group (p \< 0.001). This should be interpreted with caution.Fig. 4The results shown are the time taken to complete the trails B task minus the time taken to complete the trails A task. Standard deviations for each group are shown in the error bars. There was evidence from a post-hoc Dunn's test that the ε2+ group performed better than the ε33 (p = 0.005) group and the ε4+ group (p \< 0.001). ^\*^ denotes p \< 0.05 and ^\*\*^ denotes p \< 0.01.

3.5. Working memory {#s0075}
-------------------

As would be expected the participants had almost perfect accuracy on the 1-back task (see [Table 3](#t0015){ref-type="table"}). Accuracy was lower for the 2-back and much lower for the 3-back, as anticipated. Neither the accuracy variable nor d' were normally distributed (truncated normal distribution with an upper limit of 1.0) and it was not possible to transform them. It was not possible to calculate d'.Table 3Results from the n-back task at levels 1, 2 and 3 back.ε2+ε33ε4+AccuracyCo-efficientP-valueCo-efficientP-valueCo-efficientP-valueMulti-level regression0.036 (0.003--0.069)0.034^\*^Reference group0.008 (−0.23 to 0.040)0.590LR test for overall effectp = 0.091Reaction timeCo-efficientP-valueCo-efficientP-valueCo-efficientP-valueStatistical evidence from multi-level regression−0.001 (−0.111 to 0.110)0.987Reference group−0.021 (−0.125 to 0.083)0.694LR test for overall effectp = 0.888

The regression was therefore performed with bootstrapping as this method does not require a normal distribution. The residuals from this regression were normally distributed. The results were unchanged with bootstrapping. There appeared to be improved accuracy (3.6% increase, β = 0.036 (95% CI = 0.003--0.069), p = 0.034) in the ε22 group, although the overall likelihood test for an effect of *APOE* suggested that there was no effect (p = 0.091, see [Table 3](#t0015){ref-type="table"}). The overall r2 was 0.473.

There was no evidence that *APOE* genotype influenced reaction time to target in the 2- or 3-back n-back task (p = 0.888, see [Table 3](#t0015){ref-type="table"}).

3.6. Visual motion task {#s0080}
-----------------------

The motion task had 3 levels of speed and 2 levels for target i.e. present/absent. One participant was excluded because they had a large number of unfeasibly fast reaction times (\<120 ms) and their accuracy was at chance level. When calculating the reaction time all unfeasibly short (\<120 ms) reaction times were excluded before calculation of mean and median reaction times. A further corrected (C-mean) mean reaction time was calculated by excluding all reaction times \>2SD away from the sub-mean. Only 1 trial from one participant was excluded because of a reaction time \<120 ms.

Multi-level regression of accuracy was not possible because a normal distribution could not be obtained. The analysis proceeded using d' as this takes account of both accuracy to target and false alarms. The discriminability index (better known as d') is a measure of signal strength that takes account of signal and "noise". To prevent a false alarm rate of 0 (and thus an infinitely large d') where the false alarm rate was zero it was adjusted to be 1/N where N was the number of valid trials for that participant.

Because the within subject co-variance of the d' data structure was compound symmetric it was possible to use a repeated measures ANOVA. There was no evidence that *APOE* genotype had an effect on d' (see [Table 4](#t0020){ref-type="table"} and [supplementary Tables 4 and 5](#s0110){ref-type="sec"}).Table 4C mean reaction times and accuracy rates for the different conditions in the visual motion task. ^\*^denotes p \< 0.05.ε2+ε33ε4+MeanSDMeanSDMeanSDAccuracyTarget absentFast0.9890.020.9450.1080.9740.033Medium0.980.0290.9610.0780.9810.029Slow0.9830.0270.9520.0970.9770.040Target presentFast0.9540.0540.9290.1000.9400.068Medium0.9390.0550.9210.1070.9300.085Slow0.9390.0660.9430.0850.9460.091Repeated measures ANOVA*APOE* genotypep = 0.588Interaction between *APOE* genotype and levelp = 0.027  C mean reaction time (msec)Target absentFast1235.67756.3541072.34820.4011065.691411.334Medium1351.4981173.1531065.149781.6911079.731456.079Slow1371.3261114.9241108.585879.9181089.68483.82Target presentFast819.296301.045740.199324.114750.257252.855Medium828.271316.083747.454258.899783.043264.319Slow993.369488.757847.204316.613868.535306.196Statistical evidence from multi-level regressionCo-efficientP-valueCo-efficientP-valueCo-efficientP-value−0.014 (−0.30 to 0.002)0.106Reference group−0.007 (−0.023 to 0.008)0.354

Multilevel regression for reaction time was possible by inverse transformation of reaction time (see [Table 4](#t0020){ref-type="table"} and [supplementary Table 6](#s0110){ref-type="sec"}). There was no evidence of an *APOE* effect on reaction time.

3.7. Self-reported cognitive difficulties {#s0085}
-----------------------------------------

There was evidence from the cognitive failures questionnaire (CFQ) that self-reported cognition was worse in those with an ε4 allele (Χ^2^ = 6.051, p = 0.006, see [Fig. 5](#f0025){ref-type="fig"}A). Those with an ε4 allele also scored somewhat higher on the depression anxiety and stress scale (DASS). The overall Kruskal-Wallis test and the Dunn's post-hoc test (see [Fig. 5](#f0025){ref-type="fig"}B) suggested that those with an ε4 allele scored higher on this scale than either of the other two groups (increase = 9.7 points, overall p value = 0.024, Χ^2^ = 7.487, comparison to ε33 group p = 0.009)Fig. 5Results from the CFQ (A). Standard deviations for each group are shown in the error bars. There was evidence from a post-hoc Dunn's test that the ε4+ group had higher scores than the ε33 (p = 0.021) group and the ε2+ group (p = 0.015). As shown in figure B the ε4+ group had higher scores on the DASS. ^\*^ denotes p \< 0.05.

3.8. Effect of age group {#s0090}
------------------------

The dichotomised age groups in this study allowed us to examine differences in observed *APOE* genotype effects between young people and middle aged women. Unfortunately low numbers precluded statistical analysis, but the data are presented graphically in [Supplementary Figs. 1--7](#s0110){ref-type="sec"}. It would seem that the ε2+ positive effect on episodic memory was seen predominantly in the young people and the ε2+ effect in the trails A&B test was seen in both age groups. It appears that ε4 had slightly more effect on DASS scores in the mothers, which is surprising as there were no per genotype effects on either the Crown-Crisp or the EPDS which overlap somewhat with the DASS. Finally it seems that the higher scores on the CFQ for individuals with an ε4+ genotype was driven by the young people. Due to low numbers these findings are speculative and impossible to prove.

4. Discussion {#s0095}
=============

We found evidence to suggest that ε4 allele possession is associated with more self-reported cognitive failures, but minimal objective difference in cognitive performance compared to the reference ε33 group. We also found that possession of an ε2 allele is associated with slightly better episodic memory performance, slightly improved accuracy on the n-back task and better executive functioning (as measured by trails A&B) than the reference ε33 group. There was no evidence of a per genotype difference in reaction time, attention, verbal fluency or working memory. Effect sizes, where it was possible to calculate them, were very low. It is intriguing that the ε2 carriers, who have an up to 50% reduction in the risk of AD should demonstrate advantage in episodic memory and executive functioning tasks as these are cognitive domains affected early in the development of AD. Although Wisdom et al. found a beneficial effect of ε2 on episodic memory, the very large generation Scotland study (which had ten times the number of ε2 carriers) found no effect of ε2 on any cognitive domain examined ([@b0225], [@b0360]).

In a 2011 meta-analysis Wisdom et al. found that ε2 carriers performed better than ε4 carriers in episodic memory tests (effect size *d* = 0.09, p \< 0.05) but they did not find any statistical evidence of difference from the reference ε33 group. This was based on 6 studies and a total n of 270 ε2 carriers ([@b0360]). This finding is consistent with previous research. For example, the Religious Orders study found that episodic memory performance in ε2 carriers did not decrease with age, unlike ε33 and ε4 carriers, although at least 15% of its cohort developed AD during the ≤8 y follow-up period ([@b0350]). A similar Finnish community based study with a 3 y follow-up had similar results ([@b0175]). In a secondary analysis of data from an existing longitudinal study aimed at examining the effect of cardiovascular risk factors Blair et al. demonstrated that individuals with an ε2 allele had the least cognitive decline over a 6 y period ([@b0060]). This was a large study, with mixed ethnicity and a mean participant age of 55. Its main weaknesses were a loss to follow-up and a limited test battery. Conversely the HALCYON study, a combination of ageing cohorts, found no meta-analytic evidence of an ε2 effect on episodic memory or verbal fluency, although this was largely based on cross-sectional measures ([@b0015]). The majority of participants came from studies with a mean age in the mid 50 s. Given that many previous studies have analysed their results as ε4+ vs. ε4− it is possible that if ε2 does have a beneficial effect on cognition then including them in the ε4− (control) group may have possibly inflated findings that ε4 allele possession has a detrimental effect on cognition.

A meta-analysis in 2011 found a small effect of ε4 on episodic memory in adults without dementia, but gave the caveat that many studies had not adequately screened for dementia. Most of the studies had included mainly older adults. More recent studies have also found an effect of APOE genotype on episodic memory in later adult life, for example the limited GWAS by Andrews et al. (mean cohort age 62 y). ([@b0030]) A recent meta-analysis of the effects of *APOE* genotype on cognition in mid life reported no per genotype effect ([@b0205]). Only 8 studies with a mean participant age of less than 50 y were included.

Several studies have reported that subjective memory complaints in ε4 carriers aged over 60 are associated with greater decline in episodic memory ([@b0135], [@b0145], [@b0280]). Caselli et al. found an increased rate of subjective memory complaints in ε4 carriers in their 60 s and older ([@b0095]). Very recent work from the Australian Womens Healthy Ageing project (age of participants mid 64--77) found that whilst ε4 carriers were not more likely to report subjective memory complaints in response to a single question those that did had more decline in their episodic memory at 2 year follow up ([@b0135]). Several of these individuals subsequently developed mild cognitive impairment. It is important to note though that there is no consistent relationship between subjective memory complaints and objective decline ([@b0210]). In our study it appears that the increase in subjective memory complaints was also seen in the young people, which runs counter to the suggestion that subjective memory complaints are an early marker of cognitive decline in ε4+ individuals.

There are a number of possible biological explanations for the differences in ε2 carriers. The E2 protein is more abundant than the E4, possibly because it is more resistant to degradation ([@b0110]). It has reduced affinity for LDL receptors and binds more strongly to Aβ than other ApoE isoforms, which may lead to more efficient clearance of Aβ from cerebral blood vessels ([@b0110], [@b0305]). Recent work by Minett et al. suggests that the ε2 and ε4 alleles may have opposite effects on microglial activation ([@b0240]). It has also recently been demonstrated that the E2 isoform of ApoE increased synaptic phagocytosis by astrocytes (with possible evidence of fewer senescent synapses ([@b0105]). It has been shown in post-mortem brain studies and in PET studies of older adults that ε4 allele possession is associated with a higher amyloid plaque load ([@b0100], [@b0355]). In one study this effect was seen even in middle-aged individuals ([@b0170]). ε4 effects on neurofibrillary tangles are much less consistent ([@b0260]). Cumulatively this cell biological and neuropathological evidence goes some way towards explaining the opposing effects on the risk of AD seen with the ε2 and ε4 genotypes.

Strengths of this study include adequate screening for dementia, examination of a range of cognitive functions and prospective information on possible confounders. Eleven individuals in this study scored between 82 and 88 on the ACE-R and ten of them were young people. The mother who scored in this range had a borderline low IQ. Educational level is known to affect performance on the ACE-R ([@b0020], [@b0165], [@b0300]). All of these individuals had an MMSE score of 28 (2 young people) or higher. It is extremely unlikely that an individual in their 20 s would suffer with dementia. We can therefore be confident that no individuals with dementia were included in this study. There were more female than male participants, principally due to the study design. It is possible that ε4 effects on cognition might be more pronounced in women, but this benefit of our study design was almost certainly offset by poor recruitment ([@b0325]).

The main weakness of this study was poor recruitment. Recall by genotype is an efficient study design which maximises statistical power ([@b0335]). One drawback is that if recruitment is a problem then it is an inflexible design. Despite strenuous efforts to improve recruitment we were unable to recruit further participants. Participants in this study were better educated (mothers), more likely to come from a family that owned its own home and had higher IQs (young people) than the rest of the ALSPAC cohort. The phenomenon of differential loss to follow-up in longitudinal cohort studies is well known and it is the most likely explanation for this finding. It does however limit the generalisability of our findings. There was little evidence of a differential loss to follow-up by *APOE* genotype as the genotypes of all remaining available participants were in Hardy Weinberg Equilibrium (p = 0.016).

In conclusion this study used recall by genotype to study individuals with the full range of *APOE* genotypes. We studied younger individuals than most previous studies and used a wider range of cognitive tests. We did not find any effect of ε4 allele possession on objective cognitive test performance in young to middle aged adults, but they scored higher on the cognitive failures questionnaire (although this seemed to be more prominent in the younger age group). Our findings support the existing literature which suggests that objective ε4 effects do not develop until later adult life and may reflect the earlier onset of AD seen in this genotype group. In addition we found evidence to suggest that ε2 carriers (who have a lower risk of AD) may have mildly superior performance in executive functioning, working memory and episodic memory tasks, domains known to be affected early in the AD disease process.
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